GPR88 Modulator Chemistry for CNS Selectivity and Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GPR88 modulators exhibit suboptimal pharmacokinetic properties and off-target activity, which are undesirable for therapeutic applications in neuropsychiatric and motor disorders.
Innovation Solution
Development of a novel class of GPR88 modulators with improved pharmacokinetic properties and reduced off-target activity, specifically designed to target GPR88 receptors in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing GPR88 modulators are used, then GPR88 receptor modulation is achieved, but pharmacokinetic properties are suboptimal and off-target activity occurs
Solution Approach 1:
The patent modifies molecular parameters of GPR88 modulators by introducing specific substituents (e.g., fluorine atoms, hydroxyl groups, methoxy groups) at defined positions in the chemical structure. These parameter changes optimize pharmacokinetic properties and reduce off-target activity while maintaining GPR88 receptor modulation, directly resolving the technical contradiction between therapeutic reliability and harmful off-target effects
2Reliability
If existing GPR88 modulators are used, then GPR88 receptor modulation is achieved, but pharmacokinetic properties are suboptimal
Solution Approach 1:
The patent systematically alters chemical parameters including introducing polar groups (hydroxyl, carboxyl, amine) and adjusting molecular weight and lipophilicity through specific substituent selection. These parameter modifications optimize absorption, distribution, metabolism, and excretion characteristics, thereby improving pharmacokinetic properties and extending duration of action for therapeutic applications
Data Source
AI summary
Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.